請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26778
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林慧玲(Fei-Lin Lin Wu),柯文哲(Wen-Je Ko) | |
dc.contributor.author | Shin-Yi Lin | en |
dc.contributor.author | 林欣儀 | zh_TW |
dc.date.accessioned | 2021-06-08T07:25:12Z | - |
dc.date.copyright | 2008-08-13 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-16 | |
dc.identifier.citation | 1. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. Jama 2005;294(7):813-8.
2. O'Reilly P, Tolwani A. Renal replacement therapy III: IHD, CRRT, SLED. Crit Care Clin 2005;21(2):367-78. 3. Lameire N, Van Biesen W, Vanholder R, Colardijn F. The place of intermittent hemodialysis in the treatment of acute renal failure in the ICU patient. Kidney Int Suppl 1998;66:S110-9. 4. Pannu N, Klarenbach S, Wiebe N, Manns B, Tonelli M. Renal replacement therapy in patients with acute renal failure: a systematic review. Jama 2008;299(7):793-805. 5. Schulman G, Himmelfa J. Hemodialysis. In: Brenner BM, ed. Brenner: Brenner & Rector's The Kidney. 7 ed: Elsevier 2004:2567-98. 6. Van Biesen W, Vanholder R, Lameire N. Dialysis strategies in critically ill acute renal failure patients. Curr Opin Crit Care 2003;9(6):491-5. 7. Kumar VA, Craig M, Depner TA, Yeun JY. Extended daily dialysis: A new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis 2000;36(2):294-300. 8. Marshall MR, Golper TA, Shaver MJ, Alam MG, Chatoth DK. Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int 2001;60(2):777-85. 9. Kielstein JT, Kretschmer U, Ernst T, et al. Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis 2004;43(2):342-9. 10. Marshall MR, Ma T, Galler D, Rankin AP, Williams AB. Sustained low-efficiency daily diafiltration (SLEDD-f) for critically ill patients requiring renal replacement therapy: towards an adequate therapy. Nephrol Dial Transplant 2004;19(4):877-84. 11. Hsueh PR, Chen WH, Teng LJ, Luh KT. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 2005;26(1):43-9. 12. Lee CS, Marbury TC. Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations. Clin Pharmacokinet 1984;9(1):42-66. 13. Krueger WA, Schroeder TH, hansen M. Pharmacokinetics of antibiotics during continuous renal replacement therapy. 2005:349-59. 14. Lonnemann G, Floege J, Kliem V, Brunkhorst R, Koch KM. Extended daily veno-venous high-flux haemodialysis in patients with acute renal failure and multiple organ dysfunction syndrome using a single path batch dialysis system. Nephrol Dial Transplant 2000;15(8):1189-93. 15. Schlaeper C, Amerling R, Manns M, Levin NW. High clearance continuous renal replacement therapy with a modified dialysis machine. Kidney Int Suppl 1999(72):S20-3. 16. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000;356(9223):26-30. 17. Berbece AN, Richardson RM. Sustained low-efficiency dialysis in the ICU: cost, anticoagulation, and solute removal. Kidney Int 2006;70(5):963-8. 18. Griffith RS. Introduction to vancomycin. Rev Infect Dis 1981;3 suppl:S200-4. 19. Wilhelm MP, Estes L. Symposium on antimicrobial agents--Part XII. Vancomycin. Mayo Clin Proc 1999;74(9):928-35. 20. Pfeiffer RR. Structural features of vancomycin. Rev Infect Dis 1981;3 suppl:S205-9. 21. Jordan DC, Inniss WE. Selective inhibition of ribonucleic acid synthesis in Staphylococcus aureus by vancomycin. Nature 1959;184(Suppl 24):1894-5. 22. Watanakunakorn C. Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother 1984;14 Suppl D:7-18. 23. Murray BE, Nannini EC. Glycopeptides (Vancomycin and Teicoplanin), Streptogramins (Quinupristin-Dalfopristin), and Lipopeptides (Daptomycin). In: Mandell G, Bennett J, Dolin R, eds. Principles and practice of infectious diseases. 6 ed: Elsevier 2005. 24. Krogstad DJ, Pargwette AR. Defective killing of enterococci: a common property of antimicrobial agents acting on the cell wall. Antimicrob Agents Chemother 1980;17(6):965-8. 25. Moellering RC, Jr., Weinberg AN. Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. J Clin Invest 1971;50(12):2580-4. 26. Jaffe HW, Lewis JS, Wiesner PJ. Vancomycin-sensitive Neisseria gonorrheae. J Infect Dis 1981;144(2):198-200. 27. Finch RG, Eliopoulos GM. Safety and efficacy of glycopeptide antibiotics. J Antimicrob Chemother 2005;55 Suppl 2:ii5-13. 28. Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. Jama 1995;274(21):1706-13. 29. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39(3):309-17. 30. Rolston KV, Nguyen H, Amos G, Elting L, Fainstein V, Bodey GP. A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer. J Infect Dis 1994;169(2):350-5. 31. Saez-Llorens X, McCracken GH, Jr. Antimicrobial and anti-inflammatory treatment of bacterial meningitis. Infect Dis Clin North Am 1999;13(3):619-36, vii. 32. Kaplan SL. Management of pneumococcal meningitis. Pediatr Infect Dis J 2002;21(6):589-91; discussion 613-4. 33. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45(3):302-7. 34. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002;346(5):334-9. 35. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34(6):730-51. 36. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. Jama 1997;277(22):1794-801. 37. China IDSotRo, Association TS, Cheng MFiMoDD-L, Education FoPW-CHfIDRa, Vaccines CYLsRFfPIDa. Guidelines for the use of prophylactic antibiotics in surgery in Taiwan. J Microbiol Immunol Infect 2004;37(1):71-4. 38. DiPiro JT, Howdieshell TR. Intraabdominal infection. In: Dipiro J, Talbert R, Yee G, Matzke G, Wells B, Posey L, eds. Pharmacotherapy:A pathophysiologic approach. 6 ed: McGRAW-HILL; 2005:2055-66. 39. Larsson AJ, Walker KJ, Raddatz JK, Rotschafer JC. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother 1996;38(4):589-97. 40. Lowdin E, Odenholt I, Cars O. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1998;42(10):2739-44. 41. Moise PA, Forrest A, Bhavnani SM, Birmingham MC, Schentag JJ. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000;57 Suppl 2:S4-9. 42. Lisby-Sutch SM, Nahata MC. Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur J Clin Pharmacol 1988;35(6):637-42. 43. Knudsen JD, Fuursted K, Espersen F, Frimodt-Moller N. Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model. Antimicrob Agents Chemother 1997;41(9):1910-5. 44. Glycopeptides. In: McEvoy G, Litvak K, Welsh O, eds. AHFS :drug information: American Society of Health-System Pharmacists; 2006. 45. Matzke GR, Halstenson CE, Olson PL, Collins AJ, Abraham PA. Systemic absorption of oral vancomycin in patients with renal insufficiency and antibiotic-associated colitis. Am J Kidney Dis 1987;9(5):422-5. 46. Bryan CS, White WL. Safety of oral vancomycin in functionally anephric patients. Antimicrob Agents Chemother 1978;14(4):634-5. 47. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 1994;16(5):513-8. 48. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988;32(6):848-52. 49. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984;25(4):433-7. 50. Rotschafer JC, Crossley K, Zaske DE, Mead K, Sawchuk RJ, Solem LD. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982;22(3):391-4. 51. Moellering RC, Jr., Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981;94(3):343-6. 52. Healy DP, Polk RE, Garson ML, Rock DT, Comstock TJ. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother 1987;31(3):393-7. 53. Rodvold KA, Erdman SM, Pryka RD. vancomycin. In: Schumacher GE, ed. Therapeutic drug monitoring: Appleton & Lange; 1995:587-632. 54. Bauer LA. vancomycin. In: Bauer LA, ed. Applied clinical pharmacokinetics: McGraw-Hill; 2001:180-261. 55. Ahmed A. A critical evaluation of vancomycin for treatment of bacterial meningitis. Pediatr Infect Dis J 1997;16(9):895-903. 56. Moise-broder PA. vancomycin. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, eds. Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring 4ed: Lippincott Williams and Wilkins:328-40. 57. Dowling TC, Comstock TJ. Quantification of renal function. In: Dipiro J, Talbert R, Yee G, Matzke G, Wells B, Posey L, eds. Pharmacotherapy:A pathophysiologic approach. 6 ed: McGRAW-HILL; 2005:761-80. 58. Geraci JE, Heilman FR, Nichols DR, Ross GT, Wellman WE. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Proc Staff Meet Mayo Clin 1956;31(21):564-82. 59. Macias WL, Mueller BA, Scarim SK. Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance. Clin Pharmacol Ther 1991;50(6):688-94. 60. Aldaz A, Ortega A, Idoate A, Giraldez J, Brugarolas A. Effects of hepatic function on vancomycin pharmacokinetics in patients with cancer. Ther Drug Monit 2000;22(3):250-7. 61. Marti R, Rosell M, Pou L, Garcia L, Pascual C. Influence of biochemical parameters of liver function on vancomycin pharmacokinetics. Pharmacol Toxicol 1996;79(2):55-9. 62. Brown N, Ho DH, Fong KL, et al. Effects of hepatic function on vancomycin clinical pharmacology. Antimicrob Agents Chemother 1983;23(4):603-9. 63. Cutler NR, Narang PK, Lesko LJ, Ninos M, Power M. Vancomycin disposition: the importance of age. Clin Pharmacol Ther 1984;36(6):803-10. 64. Guay DR, Vance-Bryan K, Gilliland S, Rodvold K, Rotschafer J. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J Clin Pharmacol 1993;33(10):918-22. 65. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO, Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982;21(4):575-80. 66. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998;54(8):621-5. 67. Vance-Bryan K, Guay DR, Gilliland SS, Rodvold KA, Rotschafer JC. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993;37(3):436-40. 68. Garrelts JC, Peterie JD. Altered vancomycin dose vs. serum concentration relationship in burn patients. Clin Pharmacol Ther 1988;44(1):9-13. 69. Rybak MJ, Albrecht LM, Berman JR, Warbasse LH, Svensson CK. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990;34(5):792-5. 70. Brater DC, Bawdon RE, Anderson SA, Purdue GF, Hunt JL. Vancomycin elimination in patients with burn injury. Clin Pharmacol Ther 1986;39(6):631-4. 71. Klamerus KJ, Rodvold KA, Silverman NA, Levitsky S. Effect of cardiopulmonary bypass on vancomycin and netilmicin disposition. Antimicrob Agents Chemother 1988;32(5):631-5. 72. Ortega GM, Marti-Bonmati E, Guevara SJ, Gomez IG. Alteration of vancomycin pharmacokinetics during cardiopulmonary bypass in patients undergoing cardiac surgery. Am J Health Syst Pharm 2003;60(3):260-5. 73. Farber BF, Moellering RC, Jr. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983;23(1):138-41. 74. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 1987;83(6):1091-7. 75. Downs NJ, Neihart RE, Dolezal JM, Hodges GR. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 1989;149(8):1777-81. 76. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993;32(2):325-34. 77. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990;25(4):679-87. 78. Sorrell TC, Collignon PJ. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 1985;16(2):235-41. 79. Mellor JA, Kingdom J, Cafferkey M, Keane CT. Vancomycin toxicity: a prospective study. J Antimicrob Chemother 1985;15(6):773-80. 80. Geraci JE, Heilman FR, Nichols DR, Wellman WE. Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis; preliminary report. Proc Staff Meet Mayo Clin 1958;33(7):172-81. 81. Traber PG, Levine DP. Vancomycin Ototoxicity in patient with normal renal function. Ann Intern Med 1981;95(4):458-60. 82. Klibanov OM, Filicko JE, DeSimone JA, Jr., Tice DS. Sensorineural hearing loss associated with intrathecal vancomycin. Ann Pharmacother 2003;37(1):61-5. 83. Iwamoto T, Kagawa Y, Kojima M. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull 2003;26(6):876-9. 84. Gump DW. Vancomycin for treatment of bacterial meningitis. Rev Infect Dis 1981;3 suppl:S289-92. 85. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005;111(23):e394-434. 86. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006;42 Suppl 1:S35-9. 87. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171(4):388-416. 88. Mulhern JG, Braden GL, O'Shea MH, Madden RL, Lipkowitz GS, Germain MJ. Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients. Am J Kidney Dis 1995;25(4):611-5. 89. Pollard TA, Lampasona V, Akkerman S, et al. Vancomycin redistribution: dosing recommendations following high-flux hemodialysis. Kidney Int 1994;45(1):232-7. 90. Abbott AxSYM Vancomycin II. 2003. 91. Shargel L, Wu S, Yu ABC. Dose adjustment in renal and hepatic disease. In: Applied biopharmaceutics and pharmacokinetics. 5 ed: McGraw-Hill; 2005:673-715. 92. DeSoi CA, Sahm DF, Umans JG. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes. Am J Kidney Dis 1992;20(4):354-60. 93. Scott MK, Macias WL, Kraus MA, Clark WR, Carfagna MA, Mueller BA. Effects of dialysis membrane on intradialytic vancomycin administration. Pharmacotherapy 1997;17(2):256-62. 94. Matzke GR, Comstock TJ. Influence of renal function and dialysis on drug disposition. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, eds. Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring 4ed: Lippincott Williams and Wilkins:187-212. 95. Bressolle F, Kinowski JM, de la Coussaye JE, Wynn N, Eledjam JJ, Galtier M. Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet 1994;26(6):457-71. 96. Schulman G, Himmelfarb J. Hemodialysis. In: Brenner BM, ed. Brenner: Brenner & Rector's The Kidney. 7 ed: Elsevier; 2004. 97. Lindholm DD, Murray JS. Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis. N Engl J Med 1966;274(19):1047-51. 98. Lanese DM, Alfrey PS, Molitoris BA. Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. Kidney Int 1989;35(6):1409-12. 99. Quale JM, O'Halloran JJ, DeVincenzo N, Barth RH. Removal of vancomycin by high-flux hemodialysis membranes. Antimicrob Agents Chemother 1992;36(7):1424-6. 100. Tian Q, Gomersall CD, Leung PP, et al. The adsorption of vancomycin by polyacrylonitrile, polyamide, and polysulfone hemofilters. Artif Organs 2008;32(1):81-4. 101. Matzke GR, O'Connell MB, Collins AJ, Keshaviah PR. Disposition of vancomycin during hemofiltration. Clin Pharmacol Ther 1986;40(4):425-30. 102. Torras J, Cao C, Rivas MC, Cano M, Fernandez E, Montoliu J. Pharmacokinetics of vancomycin in patients undergoing hemodialysis with polyacrylonitrile. Clin Nephrol 1991;36(1):35-41. 103. Joy MS, Matzke GR, Frye RF, Palevsky PM. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis 1998;31(6):1019-27. 104. Touchette MA, Patel RV, Anandan JV, Dumler F, Zarowitz BJ. Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease. Am J Kidney Dis 1995;26(3):469-74. 105. Kihara M, Ikeda Y, Fujita H, et al. Effects of slowly performed daytime hemodialysis (slow HD) on the pharmacokinetics of vancomycin in hemodynamically unstable patients with renal failure. Blood Purif 1996;14(1):20-5. 106. Foote EF, Dreitlein WB, Steward CA, Kapoian T, Walker JA, Sherman RA. Pharmacokinetics of vancomycin when administered during high flux hemodialysis. Clin Nephrol 1998;50(1):51-5. 107. Bohler J, Reetze-Bonorden P, Keller E, Kramer A, Schollmeyer PJ. Rebound of plasma vancomycin levels after haemodialysis with highly permeable membranes. Eur J Clin Pharmacol 1992;42(6):635-9. 108. Mason NA, Neudeck BL, Welage LS, Patel JA, Swartz RD. Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration. Clin Nephrol 2003;60(2):96-104. 109. Lucksiri A, Scott MK, Mueller BA, Hamburger RJ, Sowinski KM. CAHP-210 dialyzer influence on intra-dialytic vancomycin removal. Nephrol Dial Transplant 2002;17(9):1649-54. 110. 台灣禮來股份有限公司. VANCOCIN CP 500mg Intravenous Injection (Vancomycin)仿單. 111. Shargel L, Wu-Pong S, Yu ABC. Dose adjustment in renal and hepatic disease. In: Applied biopharmaceutics and pharmacokinetics: McGrawHill; 2005:673-715. 112. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993;24(5):362-79. 113. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9(4):503-12. 114. Shargel L, Wu-Pong S, Yu ABC. Application of pharmacokineics in clinical situations. In: Applied biopharmaceutics and pharmacokinetics: McGrawHill; 2005:613-70. 115. Shargel L, Wu-Pong S, Yu ABC. One-compartment open model: intravenous bolus administration. In: Applied biopharmaceutics and pharmacokinetics: McGrawHill; 2005:52-72. 116. Wayne PA. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplemient. Clinical Laboratory Standard Institute (CLSI) 2006:CLSI document M100-S16. 117. Shargel L, Wu-Pong S, Yu ABC. Intravenous infusion. In: Applied biopharmaceutics and pharmacokinetics: McGrawHill; 2005:105-29. 118. DuBose TD, Jr., Warnock DG, Mehta RL, et al. Acute renal failure in the 21st century: recommendations for management and outcomes assessment. Am J Kidney Dis 1997;29(5):793-9. 119. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998;104(4):343-8. 120. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. Jama 1996;275(19):1489-94. 121. Scott MK, Mueller BA, Clark WR. Vancomycin mass transfer characteristics of high-flux cellulosic dialysers. Nephrol Dial Transplant 1997;12(12):2647-53. 122. Kielstein JT, Czock D, Schopke T, et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006;34(1):51-6. 123. Klansuwan N, Ratanajamit C, Kasiwong S, Wangsiripaisan A. Clearance of vancomycin during high-efficiency hemodialysis. J Med Assoc Thai 2006;89(7):986-91. 124. Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int 1996;50(3):929-36. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26778 | - |
dc.description.abstract | 目的:
持續型低效率血液透析過濾(sustained low efficiency daily diafiltration,SLEDD-f)結合了間斷型血液透析(intermittent hemodialysis,IHD)與連續型腎臟替代療法(continuous renal replacement therapy,CRRT)的技術與優點,主要用在加護病房內併發腎衰竭的重症病人。而外科加護病房的病人常有傷口及導管,增加革蘭氏陽性菌感染的機會。在多重抗藥性金黃色葡萄球菌(methiciilin-resistant Staphylococcus aureus,MRSA)造成的感染,vancomycin是首選的用藥。SLEDD-f使用高穿透性透析膜(high-flux dialyzer membrane),可能導致vancomycin被移除而使血中濃度不足。另外,vancomycin可能被透析膜吸附,增加一次SLEDD-f期間移除的量。因此,本研究的目的在觀察觀察以SLEDD-f做腎臟替代療法的病人,vancomycin的藥品動態學參數,同時評估一次SLEDD-f療程中,有多少比例的vancomycin會被移除,以及透過體外試驗,評估有多少量的vancomycin會被透析膜吸附。藉由以上的資料,找出在這群病人的適當給藥劑量。 方法: 本研究收入17位病人。收納條件為18歲以上,因任何原因導致腎衰竭而須使用SLEDD-f作為腎臟替代療法,且同時使用vancomycin做為感染的預防或治療之患者。vancomycin的給藥劑量與間隔由醫師或藥師決定,在起始劑量或第四劑以上後開始抽血。vancomyicn的給藥時間為SLEDD-f開始前15個小時,靜脈輸注2小時。抽血的時間為靜脈輸注結束後0、1、2、4、9個小時,SLEDD-f開始後0、2、4小時、SLEDD-f一結束時、SLEDD-f結束後1、2、3小時,共抽12個時間點的血,以FPIA測量濃度。 SLEDD-f使用的透析膜材質為helixone,表面積為1.4 m2。血液流速(QB) 200 mL/min,透析液流速(QD) 300 mL/min,超過濾速率(UFR)與補充液流速依病人所需的脫水量設定,透析時間為8小時。每2個小時收集透析期間的流出液,評估一次SLEDD-f療程所移除vancomycin的量。利用藥品動態學軟體WinNonlin中的Non-compartment模式來分析vancomycin的藥品動態學。 結果及討論: 本研究共收納16位男性,1位女性,共有10位病人被排除,排除的原因如下:1 位由於血行動力學不穩定更改腎臟替代療法,1位由於簽署放棄急救同意書而取消腎臟替代療程,1位由於腎功能恢復而取消腎臟替代療程,1位由於病危自動出院而取消腎臟替代療程,1位於簽署受試者同意書後決定退出試驗,另外2位分別因SLEDD-f開始前後的血中濃度收集不完全而無法分析其藥品動態學參數。但僅有9位男性、1位女性納入數據分析。這10位病人年齡介於33-73歲,平均55.7±12.6歲,體重介於54.2-90.6 kg,平均71.2±12.0 kg。以SLEDD-f做為腎臟替代療法的原因,8位為急性腎衰竭(acute renal failure,ARF),4位為末期腎病(end stage renal disease,ESRD)。vancomycin的劑量介於500-1000 mg,平均8.7±2.8 mg/kg。1位病人在速效劑量後進行抽血,11位病人在第四劑給藥以上進行抽血。SLEDD-f設定方面,UFR平均2247.9±288.6 mL/hr,補充液流速平均1936.0±320.7 mL/hr。 8小時的SLEDD-f療程可移除455.7±90.7 mg的vancomycin (325.3-610.0 mg),佔給藥劑量的78.0±18.1% (33.2-96.1%)。SLEDD-f前後血中濃度下降57.5±14.9%,若考慮反彈現象(rebound),則下降47.2±12.2%。rebound發生的時間介於SLEDD-f結束後1-3個小時,rebound的百分比介於透析結束時血中濃度的4.6-28.8%。SLEDD-f一開始時,血中濃度平均16.5±4.2 mg/L,SLEDD-f一結束時,血中濃度平均6.9±2.5 mg/L,低於建議的8 mg/L以上。 SLEDD-f前後藥品動態學參數的差異:排除速率常數(elimination rate constant,k):0.01 ± 0.01 vs. 0.11 ± 0.06 hr-1、半衰期(half-life,t1/2):583.8± 1037.8 (43.0-3465.0) vs. 7.7 ± 3.0 (2.9-11.5) hr及廓清率(clearance,CL):0.05± 0.07(0.00-0.22) vs. 1.5± 0.4 (0.8-2.2) mL/min/kg。體外試驗的結果顯示,在8小時內,全血溶液中的vancomycin濃度的變化均落在FPIA測量的誤差範圍內,顯示透析膜吸附vancomycin導致的濃度下降,低於FPIA偵測的範圍,因此在設計給藥劑量時,可將此部分忽略。 在以SLEDD-f作為腎臟替代療法,同時需以vancomycin做為感染的治療或預防的病人,vancomycin應在透析之後給予,給藥的頻率應依據SLEDD-f頻率調整。在未曾給藥的病人,可給予15-20 mg/kg的速效劑量,10-12 mg/kg的維持劑量。 | zh_TW |
dc.description.abstract | Background:
Sustained slow low efficiency daily diafiltration (SLEDD-f) is a conceptual and technical hybridization of continuous renal replacement therapy (CRRT) and intermittent hemodialysis (IHD). It is an increasingly used modality of renal replacement therapy for patients in intensive care unit (ICU) with acute or chornic renal failure. Vancomycin, a member of glycopeptides antibiotics, is commonly used in ICU patients for prevent or treat methicillin-resistant Staphylococcus aureas (MRSA) infection. Since the pore size of high-flux dialyzer membrane is much larger than vancomycin, post dialysis supplement dose may be required. Several studies have demonstrated that intermittent hemodilaysis with high-flux dialyzer membrane removed significant amount of vancomycin, and once weekly dose is not appropriate. However, until now, there is no relavent study on the effect of SLEDD-f on vancomycin pharmacokinetics. Therefore, the purpose of this study is to understand the pharmacokinetic of vancomycin in these patients and the amount of vancomycin removed during one course of 8-hr SLEDD-f, in order to determine an appropriate dose regimen for patients requiring SLEDD-f as renal replacement therapy. Patients and methods: Patients who used SLEDD-f as renal replacement therapy and also vancomycin for infection control or prevention were included. Vancomycin dose regimen was decided by ICU doctor or pharmacist. Serum concentration was measured after lodiang dose or the 4th doses. Vancomyicn infusion was started 15 hours before SLEDD-f start. Blood samples were drawn from arterial line at 0, 1, 2, 5, 9 hours after completion of vancomycin infusion, predialysis, 2, 4 hours after dialysis started, at the end of dialysis, 1, 2 and 3 hours after completion of dialysis. Serum vancomycin concentration was measured with fluorescence polarization immunoassay (FPIA). A high-flux helixone membrane (F60X, Fresenius) with surface area of 1.4 m2 was used for SLEDD-f. Blood flow was 200 mL/min, and dialysate flow was 300 mL/min. Ultrafiltration rate was determined by the doctor. Dialysis duration was 8 hours. Effluent (the combination of dialysate and ultrafiltrate) was collected every two hours to measure the amount of vancomycin removed during one course of SLEDD-f. Pharmacokinetic parameters were analyzed with WinNonlin professional version 4.1. Results and discussion: 17 patients were included into this study; 7 patients drop out for unstable hemodynamics (1), sign DNR (do not resuscitation) (1), renal function recovery (1), against advice discharge (1), withdraw from the study and uncomplete blood samples collection (2); only 9 males and 1 female were included for data analysis. They aged from 33-73 years, (mean±standard deviation: 55.7±12.6). The average body weight was 71.2±12.0 kg. 8 patients received SLEDD-f because of acute renal failure (ARF) and 4 for end-stage renal disease (ESRD). Vancomycin dose ranged from 500-1000 mg (mean±standard deviation: 8.7±2.8 mg/kg). Blood samples were obtained after loading dose for 1 patient and maintenance dose for 9 patients. During 8 hours of SLEDD-f, 455.7±90.7 mg of vancomycin was removed, accounted for about 78.0±18.1% (33.2-96.1%) of vancomycin dose infused. Serum concentraiton decreased by 57.5±14.9% after 8 hour of SLEDD-f, and taking into consideration of the post-dialysis rebound, the concentration decreased by 47.2±12.2%. Time of rebound ranged between 1-3 hours, and the percentage of rebond ranged from 4.6-28.8% of post dialysis concentraiton. Serum concentraiotn before SLEDD-f started was 16.5±4.2 mg/L, and concentration at the end of SLEDD-f was 6.9±2.5 mg/L, lower than the therapeutic level defined in this study (> 8 mg/L). The pharmacokinetic parameters before SLEDD-f started and during SLEDD- f were quite different: elimination rate constatnt (k) before and during dialysis, 0.01 ± 0.01 vs. 0.11 ± 0.06 hr-1, half-life (t1/2), 583.8± 1037.8 (43.0-3465.0) vs. 7.7 ± 3.0 (2.9-11.5) hr. Total clearance (CLT) before dialysis was 0.05± 0.07(0.00-0.22) mL/min/kg. Dialysis clearance (dialysance, CLD) was 1.5± 0.4 (0.8-2.2) mL/min/kg. In vitro experiment showed that during 8 hour of study, the absolute amount of vancomyicn adsorbed on the dialyzer membrane was minimal, so it can be ignored in clinical practice. Conclusion: Significant amount of vancomycin is removed during SLEDD-f, thus, post dialysis supplement dose is recommended. For patients requiring SLEDD-f as renal replacement therapy, a 15-20 mg/kg loading dose, followed by a 10-12 mg/kg maintenance dose given at the end of each dialysis is an acceptable dose regimen. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T07:25:12Z (GMT). No. of bitstreams: 1 ntu-97-R95451010-1.pdf: 5924416 bytes, checksum: 0a7c95f79f2de2db389d1b9efb069b63 (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 內容目錄 III
圖目錄 V 表目錄 VII 中文摘要 1 Abstract 3 縮寫表 5 第1章 前言 7 第2章 文獻探討 8 2.1 腎臟替代療法的原理 8 2.2 各種腎臟替代療法的簡介 8 2.2.1 連續型腎臟替代療法(continuous renal replacement therapy,CRRT) 8 2.2.2 間斷型血液透析(intermittent hemodialysis,IHD) 9 2.2.3 持續型低效率血液透析(sustained low efficiency daily dialysis,SLEDD) 10 2.2.4 持續型低效率血液透析過濾(sustained low efficiency daily diafiltration,SLEDD-f) 10 2.2.5 SLEDD、SLEDD-f與CVVH的比較 10 2.2.6 腎臟替代療法的優缺點與選擇 12 2.3 vancomycin 14 2.3.1 藥效學介紹 14 2.3.2 藥品動態學(pharmacokinetics、PK) 17 2.3.3 影響藥品動態學的狀態 21 2.3.4 副作用 23 2.3.5 療劑監測 25 2.3.6 vancomycin血中濃度的測量 27 2.3.7 檢體的處理 28 2.4 腎臟替代療法對vancomycin排除的影響 29 2.4.1 藥物相關因子 29 2.4.2 透析膜相關因子 30 2.4.3 透析設定 32 2.4.4 反彈(rebound)現象 32 2.5 IHD與SLEDD對vancomycin排出的比例、量與藥品動態學參數的影響 33 2.5.1 間斷型血液透析(intermittent hemodialysis,IHD) 33 2.5.2 持續型低效率血液透析(SLEDD) 34 第3章 研究目的及方法 38 3.1 研究目的 38 3.2 研究方法 38 3.2.1 病人的收納條件 (inclusion criteria) 38 3.2.2 SLEDD-f作業系統 39 3.2.3 SLEDD-f設定 39 3.2.4 試驗設計 40 3.2.5 相關資料收集 41 3.2.6 vancomycin血中濃度的測定 42 3.2.7 藥品動態學研究 42 3.2.8 利用三點(Cpk、Cpi、Cpo)所獲得的藥品動態學參數 46 3.2.9 劑量學研究 47 3.2.10 vancomycin透析膜吸附試驗 48 3.2.11 vancomycin濃度的測定 51 第4章 研究結果 52 4.1研究時間,地點及病人數 52 4.2病人基本資料 52 4.3 vancomycin使用情形與SLEDD-f的設定 53 4.4透析前後藥品動態學參數的變化 56 4.5 vancomycin血中濃度相對時間的變化 57 4.6各項藥品動態學參數之間的相關性與變化趨勢 60 4.6.1各種估計透析機廓清率的方法比較 60 4.6.2利用兩點(Cpk、Cpi)估計透析前藥品動態學參數與WinNonlin的參數比較 61 4.6.3利用兩點(Cpi、Cpo)估計透析期間藥品動態學參數與WinNonlin的參數比較 64 4.6.4透析機廓清率與全身廓清率的關係 65 4.6.5影響SLEDD-f移除量的因子 66 4.7劑量學研究 66 4.8透析膜吸附試驗 67 4.8.1全血溶液 67 4.8.2 0.9%生理食鹽水溶液 71 第5章 討論 73 5.1 SLEDD-f病人vancomycin藥品動態學分析 73 5.2 SLEDD-f病人vancomycin血中濃度的變化 77 5.3 劑量學研究 80 5.4 透析膜吸附的vancomycin 86 5.5 研究限制 88 5.5.1 病人數 88 5.5.2 給藥劑量與透析設定 88 5.5.3 試驗設計 89 5.5.4 vancomycin療效的評估 90 第6章 結論 91 第7章 附錄 92 7.1 劑量學研究 92 7.2 分佈體積的決定 101 參考資料 105 | |
dc.language.iso | zh-TW | |
dc.title | vancomycin在使用持續性低效率血液透析過濾(SLEDD-f) 的病人之藥品動態學與劑量學研究 | zh_TW |
dc.title | Pharmacokinetics and dosing of vancomycin in sustained low efficiency daily diafiltration (SLEDD-f) | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.advisor-orcid | ,柯文哲(wenje@ha.mc.ntu.edu.tw) | |
dc.contributor.coadvisor | 林淑文(Shu-Wen Lin) | |
dc.contributor.oralexamcommittee | 沈麗娟(Li-Jiuan Shen),黃金鼎(Jin-Ding Huang) | |
dc.subject.keyword | 萬古黴素,藥品動態學(藥動學),持續型低效率血液透析過濾,劑量學, | zh_TW |
dc.subject.keyword | vancomycin,pharmacokinetics,sustained-slow low efficiency dialy hemoidalfiltratio (SLEDD-f),dosage, | en |
dc.relation.page | 113 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2008-07-17 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 5.79 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。